Maze Therapeutics' (NASDAQ:MAZE - Get Free Report) quiet period is set to expire on Wednesday, March 12th. Maze Therapeutics had issued 8,750,000 shares in its IPO on January 31st. The total size of the offering was $140,000,000 based on an initial share price of $16.00. During the company's quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.
Wall Street Analysts Forecast Growth
MAZE has been the subject of several recent analyst reports. JPMorgan Chase & Co. initiated coverage on shares of Maze Therapeutics in a research note on Tuesday, February 25th. They set an "overweight" rating and a $30.00 price objective for the company. Leerink Partnrs raised shares of Maze Therapeutics to a "strong-buy" rating in a research note on Tuesday, February 25th. Guggenheim started coverage on shares of Maze Therapeutics in a research report on Tuesday, February 25th. They set a "buy" rating and a $19.00 price target on the stock. Leerink Partners started coverage on shares of Maze Therapeutics in a research report on Tuesday, February 25th. They set an "outperform" rating and a $28.00 price target on the stock. Finally, TD Cowen upgraded shares of Maze Therapeutics to a "strong-buy" rating in a research report on Tuesday, February 25th. Three analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Maze Therapeutics has an average rating of "Buy" and a consensus price target of $25.67.
Check Out Our Latest Research Report on MAZE
Maze Therapeutics Trading Up 2.3 %
Shares of NASDAQ MAZE traded up $0.27 during midday trading on Friday, hitting $12.00. 104,946 shares of the company traded hands, compared to its average volume of 280,706. Maze Therapeutics has a 12-month low of $10.08 and a 12-month high of $17.00.
About Maze Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Read More
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
